{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T19:27:40Z","timestamp":1757705260134,"version":"3.41.2"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T00:00:00Z","timestamp":1722297600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Cardiac amyloidosis is a cardiomyopathy resulting from the extracellular deposition of proteins such as transthyretin (TTR). We present the case of a 72-year-old male with hereditary cardiac amyloidosis. After confirming the diagnosis, tafamidis, a TTR stabilizer, was administered. Remarkably, tafamidis, when coupled with peritoneal dialysis for chronic kidney disease, maintained stability in both cardiac and renal functions. Previous studies have demonstrated the efficacy of tafamidis in reducing all-cause mortality and cardiovascular hospitalizations, although its use in severe renal failure lacks specific evaluation. This case suggests a potential application of tafamidis in moderate\u2013severe kidney disease, emphasizing the need for further research in this population.<\/jats:p>","DOI":"10.1093\/ckj\/sfae233","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T17:00:11Z","timestamp":1722358811000},"source":"Crossref","is-referenced-by-count":1,"title":["Experience with tafamidis in peritoneal dialysis for a patient diagnosed with transthyretin cardiac amyloidosis"],"prefix":"10.1093","volume":"17","author":[{"given":"Diego L\u00f3pez","family":"Fazlic","sequence":"first","affiliation":[{"name":"Cardiology Department, Nuestra Se\u00f1ora de la Candelaria University Hospital , Santa Cruz de Tenerife, Tenerife , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8450-0482","authenticated-orcid":false,"given":"Samuel Abrante","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Nephrology Department, Nuestra Se\u00f1ora de la Candelaria University Hospital , Santa Cruz de Tenerife, Tenerife , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micaela","family":"Gerard","sequence":"additional","affiliation":[{"name":"Nephrology Department, Nuestra Se\u00f1ora de la Candelaria University Hospital , Santa Cruz de Tenerife, Tenerife , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edduin Mart\u00edn","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Nephrology Department, Nuestra Se\u00f1ora de la Candelaria University Hospital , Santa Cruz de Tenerife, Tenerife , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro Alonso","family":"Bethencourt","sequence":"additional","affiliation":[{"name":"Nephrology Department, Nuestra Se\u00f1ora de la Candelaria University Hospital , Santa Cruz de Tenerife, Tenerife , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Vannini","sequence":"additional","affiliation":[{"name":"Cardiology Department, Nuestra Se\u00f1ora de la Candelaria University Hospital , Santa Cruz de Tenerife, Tenerife , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celestino Hern\u00e1ndez","family":"Garc\u00eda","sequence":"additional","affiliation":[{"name":"Cardiology Department, Nuestra Se\u00f1ora de la Candelaria University Hospital , Santa Cruz de Tenerife, Tenerife , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel Mac\u00eda","family":"Heras","sequence":"additional","affiliation":[{"name":"Nephrology Department, Nuestra Se\u00f1ora de la Candelaria University Hospital , Santa Cruz de Tenerife, Tenerife , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"2024081615054686400_bib1","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2024081615054686400_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2024081615054686400_bib3","doi-asserted-by":"crossref","first-page":"e008193","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193","article-title":"Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Elliott","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2024081615054686400_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Chen","year":"2018","journal-title":"N Engl J Med"},{"key":"2024081615054686400_bib5","doi-asserted-by":"crossref","first-page":"101667","DOI":"10.1016\/j.cpcardiol.2023.101667","article-title":"Real-world efficacy of tafamidis in patients with transthyretin amyloidosis and heart failure","volume":"48","author":"Ghoneem","year":"2023","journal-title":"Curr Probl Cardiol"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ckj\/advance-article-pdf\/doi\/10.1093\/ckj\/sfae233\/58683061\/sfae233.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/8\/sfae233\/58836950\/sfae233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ckj\/article-pdf\/17\/8\/sfae233\/58836950\/sfae233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T15:31:22Z","timestamp":1723822282000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/doi\/10.1093\/ckj\/sfae233\/7723711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":5,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfae233","relation":{},"ISSN":["2048-8505","2048-8513"],"issn-type":[{"type":"print","value":"2048-8505"},{"type":"electronic","value":"2048-8513"}],"subject":[],"published-other":{"date-parts":[[2024,8]]},"published":{"date-parts":[[2024,7,29]]},"article-number":"sfae233"}}